
Pfizer and Medivation have written off their Alzheimer’s candidate dimebon after another Phase III failure. The firms said a 12-month …

Despite many years of relentless research efforts, Alzheimer’s disease, the most common form of dementia, remains impossible to cure. According …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

